Monitor for future Form 4 filings by Maraganore to track insider buying or selling activity, which could signal conviction or concern. No immediate trading catalyst from this filing.
Price Chart
Executive Summary
John Maraganore filed a Form 3 initial statement of beneficial ownership with City Therapeutics, Inc., reporting 859,933 shares of common stock held directly, 637,014 shares held indirectly through two irrevocable trusts, and options to acquire 135,611 shares. This is a routine insider filing required upon becoming a reporting person and contains no material financial or operational news.
Key Facts
- John Maraganore filed Form 3 as an officer/director/beneficial owner of City Therapeutics, Inc.
- Direct holdings: 859,933 shares of common stock.
- Indirect holdings: 318,507 shares via John M. Maraganore 2021 Irrevocable Trust and 318,507 shares via Christine Maraganore 2021 Irrevocable Trust.
- Also holds Series Seed convertible preferred stock convertible into 549,150 common shares and Series A convertible preferred stock convertible into 61,609 common shares.
- Stock option to buy 135,611 shares at $5.36, vesting in 48 equal monthly installments starting June 3, 2026.
- Filing includes a standard power of attorney for Section 16 filings.
Financial Impact
No financial impact — this is a standard initial ownership disclosure with no transaction or corporate event.
Risk Factors
- No material risks identified from this routine filing.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-116349 |
| Document: 0001104659-26-116349-index-headers.html | 0001104659-26-116349 |
| Document: 0001104659-26-116349-index.html | 0001104659-26-116349 |
| Document: 0001104659-26-116349.txt | 0001104659-26-116349 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | SC 13D | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 26, 2026 1d ago | SC 13G | $20.79 | awaiting T+5 | — | $20.86 (+0.34%) |
Oct 22, 2026 5d ago | SC 13G | $20.77 | awaiting T+5 | — | $20.86 (+0.43%) |
Oct 19, 2026 8d ago | Insider Cluster | $20.83 $20.86 | ▲ +0.14% | ▲ +0.06% | $20.86 (+0.14%) |
Oct 19, 2026 8d ago | Press Release | $20.83 $21.19 | ▲ +1.73% | ▲ +1.70% | $20.86 (+0.14%) |
Oct 16, 2026 11d ago | 424B4 | $21.46 $20.79 | ▼ −3.12% | ▼ −2.98% | $20.86 (−2.80%) |
Oct 16, 2026 11d ago | EFFECT | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
Oct 15, 2026 12d ago | 3 | $22.40 $20.77 | ▼ −7.28% | ▼ −6.85% | $20.86 (−6.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers